VEGF antagonists

Expert Opinion on Biological Therapy

Volumn 1, Issue 4, 2001, Pages 703-718

  Hasan, J ^a   Jayson, G C ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

Angjogenesis; Antagonists; VEGF

Indexed keywords

ANTIBODY; ANTISENSE OLIGODEOXYNUCLEOTIDE; ENDOTHELIAL CELL GROWTH FACTOR; GROWTH FACTOR RECEPTOR; LYMPHOKINE; PROTEIN TYROSINE KINASE; RECEPTOR PROTEIN TYROSINE KINASES; RIBOZYME; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ADULT; CHEMICAL STRUCTURE; GENETICS; HUMAN; METABOLISM; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PATHOPHYSIOLOGY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; REVIEW;

ADULT; ANTIBODIES; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; ENDOTHELIAL GROWTH FACTORS; HUMAN; LYMPHOKINES; MOLECULAR STRUCTURE; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RNA, CATALYTIC;

EID: 0035409903     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.1.4.703     Document Type: Article

References (152)

1. FOLKMAN J: Anti angiogenesis: new concept for therapy of solid tumours. Ann. Sur& (1972) 175:409-416.
2. FOLKMAN J: What is the evidence that tumours arc angiogenesis dependent?J. NatL Cancer Inst. (1990) 82:4-6.
3. The Role of VEGF. Bicknell R, Lewis CE, FerraraN (Eds.), Tumour Angiogenesis; Oxford Univ. Press (1997).
4. DE VITA VT JR, HELLMAN S, ROSENBERG SA: Cancer, Principles and
5. Practice of Oncology. Lippincot-Raven (1997).
6. SENGER DR, GALLISJ, DVORAK AM et al.: Tumour cells secrete a vascular permeability factor that promotes accumulation of ascitic fluid. Scitnce (1983) (219):983-985.
7. OLSON TA, MOHANRAJ D, CARSON
8. LF et al.: Vascular permeability factor gene expression in normal and neoplastic human ovaries. Cancer Res. (1994) 54:276-280.
9. BROWN LF, BERSEB, JACKMANRW et al.: Expression of vascular permeability factor (VEGF) and its receptors in adenocarcinomas of the gastrointestinal tract. Cancer Res. (1993) 53:4727-4735.
10. FERRARA N, WINER J, BURTON T et al.: Expression of vascular endothelial growth factor does not promote transformation but confers a growth advantage in vivo to Chinese hamster ovary cells.J. Clin. Invest. (1993) 91:160-170.
11. OLOFFSONB,PAJUSOLAK,VON EULER G et al.: Genomic organisation of the mouse and human genes for vascular endothelial growth factor B(VEGF-B) and characterisation of a second splice isoform. J. BioL Chem. (1996) 271:19310-19317.
12. JOUKOV V, PAJUSOLA K, KAIPANEN A et al.: A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4(VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBOJ. (1996) 15:1751.
13. YAMADAY.NEZUJ.SHIMANEMrr al.: Molecular cloning of a novel vascular endothelial growth factor, VEGF-D. Genomics (1997) 42:483-488.
14. OGAWA S, OKU A, SAWANO A et al.: A novel type of vascular endothelial growth factor, VEGF-E (NZ-7 VEGF), preferentially utilises KDR/Flk-1 receptor and carries a potent mitotic activity without heparin binding domain.J. BioL Chem. (1998) 273:31273-31282.
15. MAGUONE D, GUERRIERO V, VIGLIETTO G et al.: Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. Proc. NatLAcaJ. Sei USA (1991) 88:9267-9271.
16. KIM KJ, LI B, FERRARA N et al.: The vascular endothelial growth factor proteins: identification of biologically relevant regions by neutralising monoclonal antibodies. Growth Factors(1992) 7:53-64.
17. ROECKLW,HECHTD,SZTAJERHrt al.: Differential binding, characterisation and cellular inhibition by soluble VEGF receptors 1 and 2. Experimental Cell Res. (1998) 241:161-170.
18. TERMAN BI, KHANDNE L, DOUCHER VEIMAZEN M et al.: VEGF receptor subtypes KDR and Flt-1 show different sensitivities to heparin and placenta growth factor. Growth Factors (1994) 11:187-195-
19. ZHANG HT, SCOTT PA, MORBIDELLI L et al.: The 121 amino acid isoform of
20. vascular endodielial growth factor is more strongly tumourigenic than other splice variants. Br. J. Cancer (2000) 83:63-68.
21. • Demonstrated greater biological activity forVEGF121 as compared to other VEGF isoforms.
22. SHIMA DT, ADAMS AP, FERRARA N et al.: Hypoxie induction of vascular endothelial growth factor in retinal cells: identification and characterisation of vascular endodielial growth factor (VEGF) as the sole mitogen. Mol Med. (1995) 1:182-193.
23. SHWEIKID, ITIN A, SOFFER D, KESHET E: Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature (1992) 359:843-845.
24. •• Showed that VEGF-mediated angiogenesis is induced by hypoxia.
25. BANAIS, SHWEIKI D, PINSON A etaL Upregulation of vascukr endothelial growth ' factor expression induced by myocardial ischaemia: implications for coronary angiogenesis. Cardiovosc. Res. (1994) 28:1176-1179.
26. ILIOPOULOS O, LEVY AP, JIANG G et al.: Negative regulation of hypoxiainducible genes by the von Hippel Lindau protein. Proc. NatL Acad. Sei. USA (1996) 93:10595-10599.
27. BLANCHER C, HARRIS AL: The molecular basis for the hypoxia response pathway: tumour hypoxia as a therapy target. Cancer Métastases Rev. (1998) 17:187-194.
28. MAXWELL PH, DACHS GU.GLEADLE JM et al.: Hypoxia inducible factor-1 modulates gene expression in solid tumours and influences both angiogenesis and tumour growth. Proc. NatlAcad. Sei. USA (1997) 94:8104-8109.
29. WEISENER MS, TURLEY H, ALLEN WE et al.: Induction of endothelial PAS domain protein-1 by hypoxia: characterisation and comparison with hypoxia-inducible factor-1 alpha. Blood (1998) 92:2260-2268.
30. GASPARINI G: Prognostic value of vascukr endothelial growth factor in breast cancer. Oncologist 2000 5(Suppl.):37-44.
31. SHIBUYAM,YAMAGUCHIS,IKEDAT et al.: Nucleotide sequence and expression of a novel human receptor- type tyrosinc kinase (fit) closely related to the fms family. OncoSene( 1990) 5:519-524.
32. TERMANBI, CARRION ME, KOVACS E et al.: Identification of a new endothelial cell growth factor receptor tyrosine kinase. Oncogene (1991) 6:1677-1683.
33. LARRIVEE B, KARSAN A: Signalling pathways induced by vascular cndothellal growth factor (rev). Int]. Mol Med. (2000) 5(5):447-456.
34. HUBBARD SR: Structural analysis of receptor tyrosine kinases. Prog. Biophys. MoL Blol. (1999) 71:343-358.
35. GERBER HP, MCMURTREY A, KOWALSKIJ et al.: Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidyl inositol 3' kinase/Akt signal transduction pathway. Requirement for flk-1/lcdr activation.J. BioL Chem. (1998) 273:30336-30343.
36. MILLAUERB, PLATE KH.SHAWVER LK et al.: Glioblastoma growth inhibited in vivo by dominant negative flk-1 mutant. Nature (1994) 367:576-579.
37. BERNATCHEZPN.SOKERS.SIROIS MG: Vascular endothelial growth factor effect on endothelial cell proliferation, migration and platelet activating factor synthesis is flk-1 dependent.J. BioL Chem. (1999) 274:31047-31054.
38. SOKER S, TAKASHIMA S, MIAO HQ et al.: Neuropilin-1 is expressed by endothelial cell and tumour cells as an isoform specific receptor for vascular endothelial growth factor. O//(1998) 92:735-745.
39. SENGER DR, LEDBETTER SR, DETMAR M et al.: Stimulation of endothelial cell migration by VPF/VEGF through cooperative mechanisms involving the ttyp3 integrin, osteopontin and thrombin. Am.J.PathoL (1996) 149:293305.
40. SENGER DR, CONOLLY DT, VAN DE WATER L et al.: Purification and NH2 terminal amino acid sequence of guinea pig tumour secreted vascular permeability factor. Cancer Res. (1990) 50:1774-1778.
41. STACKER SA, VITALI A, CAESAR C et al.: A mutant form of vascular endothelial growth factor(VEGF) that lacks VEGFR-2 activation retains the ability to induce vascular permeability.J. BiûL Chem. (1999) 49:34884-34892.
42. KIM KJ, LI B, WINER J et al.: Inhibition of vascular endothelial growth factor induced angiogenesis suppresses tumour growth in vivo. Nature (1993) 362:841-844.
43. TANIGAWAN.AMAYAH, MATSUMARA M étal: Correlation , between expression of vascular endothelial growth factor and tumour vascularity, and patient outcome in human gastric carcinoma.J. Clin. OncoL (1997) 15:826832.
44. LINDERHOLM B, TAVELIN B, GRANKVIST K et al.: Vascular endothelial
45. growth factor protein - a predictor of survival in primary breast cancer. Proc. of ASCO (1998) Absract 386.
46. O' BYRNE KJ, KOUKOURAKIS MI, GIATROMANOLAKIA et al: Vascular endothelial growth factor, platelet derived growth factor and angiogenesis in non small cell lung cancer. Br. J. Cancer (2000) 82(8):1427-1432.
47. MATTERN J, KOOMAGI R, VOLM M: Association of vascular endothelial growth factor expression with intra tumoural microvessel density and tumour cell proliferation in human epidermoid lung carcinoma. Br.J. Gzr(1996) 73:931934.
48. YUANA.CHONG-JENYU.SOW HSONG KUO ctal: Vascular endothelial growth factor 189 mRNA isoform expression specifically correlates with tumour angiogenesis, patient survival and post operative relapse in patients with non small cell lung cancer.J. Clin. OncoL (2001) 19:432-441.
49. TAKAHASHIY.KTTADAIY.BUCANA CD et al.: Expression of vascular endothelial growth factor and its receptor KDR correlates with vascularity, métastases and proliferation of human colon cancer. Cancer Res. (1995) 55:3964-3968.
50. WEIDNER N, CARROLL PR, FLAX J et al.: Tumour angiogenesis correlates with métastases in invasive prostate carcinoma. Am.]. Pathol (1993) 143:401-409.
51. • Confirmed that microvascular density correlates with métastases in Invasive prostatic carcinoma, confirming similar observations in breast and lung cancers.
52. WUH,MCLEODAR,LIMAWFrtz£: Identification and partial purification of human dsRNAse activity. A novel terminating mechanism for oligoribonucleotide antisense drugs. J. BioL Chem. (1998) 273:2532-2542.
53. MCMAHONG: Vascular endothelial growth factor signalling in tumour angiogenesis. Oncologist (2000) 5(SuppI.l):3-10.
54. SALEHM, STACKER SA, WILKSAF: Inhibition of growth of C6 glioma cells in vivo by expression of antisense vascular endothelial growth factor sequence. Cancer Res. (1996) 56:393-401.
55. NGUYEN JT, WU P, HLATKY L et al.: Adeno associated virus mediated delivery of anti-angiogenic factors as an ami tumour strategy. Cancer Res. (1998) 58:5673-5677.
56. CLAFFEYKP, BROWN LF.DELAGUILA LF et al.: Expression of vascular permeability factor/vascular endothelial
57. factor by melanoma cells increases tumour growth, angiogenesis and experimental métastases. Cancer Res. (1996) 56:172-181.
58. • Showed correlation between VEGF expression and experimental tumour angiogenesis and métastases in an in vitro model.
59. CHENG SY, HUANG HJ, NAGANE M et al.: Suppression of glioblastoma angiogenicity and tumourigenicity by inhibition of endogenous suppression of vascular endothelial growth factor. Proc. NatLAcaJ. Sei. USA (1996) 93:8502-8507.
60. WOLFF JA, MALONE RW, WILLIAM P et al.: Direct gene transfer into mouse muscle in vivo. Scienct (1990) 247:14651468.
61. NGUYENJT: VEGF as a target for cancer gene therapy. Cancer gene therapy 2000: past achievements and future challenges. H Kluwer (Ed.), Acad./PIenum publishers.
62. PARRY TJ, CUSHMAN C, GALLEGOS AM ttal.: Bioactivity of anti-angiogenic ribozymes targeting Flt-1 and KDR mRNA. Nucleic acid Res. (1999) 27:2569-2577.
63. PARKER VP, SANDBERG JA, SMITH Jet al.: Phase I and pharmacokinetic studies of Angiozyme, a synthetic ribozyme targeting the VEGF receptor Flt-1. Proc. ASCO (2000) Abstract 703.
64. WENGDE,WEISSP,GANAPATHIRrf al.: A Phase I/II study of repetitive dose Angiozyme, a ribozyme targeting the Flt-1 receptor for VEGF. Proc. Eleventh NCIEORTC-AACR symposium (2000) Abstract 267.
65. YOKrrAA,ASANOM,OKAMOTOTrt al.: Suppression of ascites formation and reaccumulation associated with human ovarian cancer by anti-VPF monoclonal antibody in vivo. Anti-Cancer Res. (2000) 20(1A):155-160.
66. PRESTA LG, CHEN H, O'CONNOR SJ et al.: Humanisation of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumours and other disorders. Cancer Res. (1997) 57:4593-4599.
67. GORDON MS, MARGOLIN K, TALPAZ M et al.: Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor antibody in patients with advanced cancer.J. Clin. Oncol. (2001) 19:843-850.
68. •• Demonstrated biological activity of rhumAb VEGF in humans.
69. REESE D, FRÖHLICH M.BOK R et al.: A Phase II trial of humanised monoclonal anti-vascular endothelial growth factor antibody (RhuMAb VEGF) in hormone
70. refractory prostate cancer (HRPC). Proc. ASCO (1999) Abstract 1355.
71. SLEDGE G, MILLER K, NOVOTNY W et al.: A. Phase II trial of single agent rhuMAb VEGF (recombinant humanised monoclonal antibody to vascular endothelial cell growth factor) in patients •with relapsed metastatic breast cancer. Proc. ASCO (2000) Abstract 5C.
72. DEVORE RF, FEHRENBACHER L, HERBST SR et al.:A randomised Phase II trial comparing RhuMAb VEGF plus Carboplatin/Paclitaxel(CP) to CP alone in patients with stage III/IV non small cell lung cancer. Proc. ASCO (2000) Abstract 1896.
73. BERGSLAND E, HURWTTZ H, FEHRENBACHER L et al.: A randomised Phase II trial comparing RhuMAb VEGF plus 5-fluorouracil/leucovorin(FU/LV) to FU/LV alone in patients with metastatic colorectal cancer. Proc. ASCO (2000) Abstract 939.
74. ASANOM,YUKITAA,MATSUMOTO T et al.: An and human VEGF monoclonal antibody MV833 that exhibits potent and tumour activity in vivo. Hybridomn (1998) 17(2):185-190.
75. BURGER AM, HENDRIKS HR, TANG T et al.: Enhanced and tumour activity of anri-VEGF antibody HuMV833 given in combination with gemcitabine in human pancreatic tumour xenografts. Proc. Eleventh NCI-EORTC-AACR symposium (2000) Abstract 579.
76. JAYSON GC, MULATERO C, RANSON M étal: Anti-VEGF antibody HuMv833: An EORTC biological treatment development. Phase I toxicity, pharmacokinetic and pharmacodynamic trial. Proc. Eleventh NCI-EORTC-AACR symposium. Abstract 270.
77. SKOBE M, ROCKWELL P, GOLDSTEIN N et al: Halting angiogenesis suppresses carcinoma cell invasion. Nat. Med. (1997) 3:1222-1227.
78. PREWETTM,HUBERJ,LIYrt:Anri vascular endothelial growth factor receptor(flk-l) monoclonal antibody inhibits tumour angiogenesis and growth of several mouse and human tumours. Cancer Res. (1999) 59:5209-5218.
79. INOUE K, SLATON JW, DAVIS DW et al: Treatment of human metastatic transitional cell carcinoma of the bladder in a murine model of the and vascular endothelial growth factor receptor monoclonal antibody DC101 and Paclitaxel. din. Cancer Res. (2000) 6(7):2635-2643.
80. XIAOQIANG K, JACK SHI, PATEL D et al.: Enhanced suppression of melanoma tumour growth and metastasis by combined therapy with anti-VEGF receptor and ami gp 75 monoclonal antibody. Proc. Eleventh NCI-EORTC-AACR symposium. Abstract 499.
81. ZHENPING ZHU, W11TE L, HICKLIN DJ et al.: Safety profile in primates and antiangiogenic activity in murine and canine models of a chimeric antibody against the vascular endothelial growth factor rcceptor2. Proc. ASCO (2000) Abstract 1793.
82. LIN P, SANKARS, SHAN S et al: Inhibition of tumour growth by targeting tumour endothelium using a soluble vascular endothelial growth factor receptor. Cell Growth Differ. (1998) 9:49-58.
83. GOLDMAN CK, KENDALL RL, CABRERA G et al.: Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumour growth, métastases and mortality rate. Proc. NatL AcaJ. Sei. USA (1998) 95:8795-8800.
84. HOLMGREN L O'REILLY MS, FOLKMAN J: Dormancy of micro métastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nature Mtd. (1995) 1:149153.
85. GERBER HP, RYAN AM, FERRARA N et al.: Vascular endodielial growth factor couples hypertrophie cartilage remodelling, ossification and angiogenesis during endochondral bone formation. Nature Med. (1999) 5:623-628.
86. SOKERS, SCHUCHG, MACHLUFM et al.: Novel delivery system of a VEGF antagonist using encapsulated cells for tumour therapy. Proc. ASCO (2000) Abstract 1877.
87. MENDEL DB, LAIRD AD, SMOLICH BD et al.: Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity as an antiangiogenic agent. Anticancer Drug Design (2000) 15:29-41.
88. FONG TA, SHAWVER LK, SUN L et ab. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor(flk/kdr) that inhibits tyrosine kinase catalysis, tumour vascularisation and growth of multiple tumour types. Cancer Res. (1999) 59:99-106.
89. • Demonstrated activity of SU-5416 - an RTK inhibitor in in vivo models.
90. ARMESILLAAL,LORENZOE,GOMEZ DEL ARCO P etaL :Vascular endothelial growth factor activates nuclear factor of activated T cells in human endothelial cells:
91. a role for tissue factor gene expression. MoL Cellular BiaL (1999) 19:2032-2043.
92. CHERRINGTON JM, LAIRD AD, SHAWVER LK et al.: Activity profile of SU5416, a small molecule Flk-1/KDR inhibitor, in tumour xenograft models. Clin, Cancer fcs. (Suppl.) (1999) Abstract 10.
93. VAJKOCZYP, MENGER MD, VOLLMARB et ûL: Inhibition of tumour growth, angiogenesis and microcirculation by the novel Flk-1 inhibitor SU5416 as assessed by intravital multifluorescence videomicroscopy. Neoflasia (1999) 1:31-41.
94. SHAHEENRM.DAVISDW.LIUWrt al.: Anti-angiogenic therapy targeting the tyrosine kinasc receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver métastases and induces rumour and endothelial cell apoptosis. Cancer fcs. (1999) 59:54125416.
95. ROSEN L.MULAYM, MAYERS A et al.: Phase I dose escalating trial of SU5416, a novel angiogenesis inhibitor in patients with advanced malignancies. Pror. ASCO (1999) Abstract 618.
96. CROPPGF, HANNAH AL:SU5416 a molecularly targeted novel anti-angiogenesis drug: Clinical pharmacokinetics and safety review. Proc. Eleventh NCI-EORTC-AACR symposium. Abstract 262.
97. GIACCONE G, ROSEN L, KUENEN B et al.: Dose finding study of Cisplatin, Gemcitabine and SU5416 in patients with advanced malignancies. Proc. Eleventh NCIEORTC-AACR symposium. Abstract 263.
98. MILES S, ARASTEH K, GILL PttaL-.A multi-centre dose escalating study of SU5416 in AIDS-related kaposi's sarcoma. Proc. ASCO (2000) Abstract 683.
99. ROSEN PJ, AMADO R, HECHTJR et al.: A Phase I/II study of SU5416 in combination wirn 5FU/LV in patients with metastatic colorectal carcinoma. Proc. ASCO (2000) Abstract 5D.
100. SHAWVER LK, STRAWN LM, FONG TA et al.: U6668 is a potent broad spectrum angiogenesis inhibitor that exhibits antitumour properties. Proc. Am. Assoc. Cancer Res. (1999) 40:723a.
101. LJANGC.SUNL.TRANNrtaZ: Discovery and design of angiogenesis inhibitors that inhibit tyrosine kinase activities associated with VEGF, FGF and PDGF. Proc. Am. Assoc. Cancer Res. (1999) 40:68a.
102. LAIRD AD, VAJKOCZYP, SHAWVER LK et al.: SU6668 b a potent antiangiogenesis and anti-tumour agent that induces regression of established tumours.
103. Cancer Res. (2000) 60(15):4152-60.
104. • Established in viva efficacy of oral RTK inhibitors.
105. MEETING REPORT: Biological basis of anti-angiogenic therapy. Acta Histochtmica (2000)102:117-127.
106. ROSEN L, HANNAH A, ROSEN P et al.: Phase I dose escalating trial of oral SU6668, a novel multiple receptor tyrosine Icinase inhibitor in patients with advanced malignancies. Proc. Eleventh NCI-EORTCAACR symposium Abstract 581.
107. ROSEN L, HANNAH A, ROSEN P et al.: Phase I dose escalating trial of oral SU66G8, a novel multiple receptor tyrosine kinase inhibitor in patients with selected advanced malignancies. Proc. ASCO (2000) Abstract 708.
108. SMOLICHBD,YU£NHA,WESTKArt aL SU5416 and SU6668 inhibit biological function of c-kit in a myeloid leukaemia cell line and in AML blasts. Proc. Eleventh NCIEORTC-AACR symposium. Abstract 265.
109. HENNEQUIN LF, THOMAS AP, JOHNSTONE C et al.: The design and synthesis of a novel orally active VEGF receptor tyrosine kinase inhibitor. Proc. Am. Assoc. Cancer Res. (1999) 40:4159.
110. WEDGE SR.OGILVIEDJ, DUKES M et al.: ZD4190: an orally active inhibitor of vascular endothelial growth factor signalling with broad spectrum and tumour efficacy. Cancer Res. (1999) 60:970-975.
111. • Established in vivo efficacy of oral RTK inhibitors.
112. WEDGE SR, OGILVIE DJ, DUKES M et al.: Chronic and acute effects of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor on established human tumour xenografts. Proc. Eleventh NCI-EORTC-AACR Symposium. Abstract 268.
113. WOOD JM. BOLD G, BUCHDUNGER E et al.: PTK787/ZK222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinase, impairs vascular endothelial growth factor induced responses and tumour growth after oral administration. Cancer Res. (2000) 15:2178-2189.
114. • Established in vivo efficacy of oral RTK inhibitors.
115. DREVSJ.HOFMANNI, HUGENSCHMIDT H et al.: Effects'of PTK787/ZK222584, a specific inhibitor of VEGF receptor tyrosine kinase on primary tumours, métastases, vessel density and blood flow in a murine renal cell carcinoma model. Cancer Res. (2000) 60(17):48194824.
116. XU L, YONEDAJ, HERRERA C et al.: Inhibition of malignant ascites and growth of human ovarian carcinoma by oral administration of a potent inhibitor of the vascular endothelial growth factor receptor tyrosine kinases. Int. J. OncoL (2000) 16:445-454.
117. DREVS J, MROSS K, REUSCH P et al: Phase I dose escalation pharmacokinetic study of a novel vascular endothelial growth factor receptor (VEGF) inhibitor, PTK787/ ZK222584 (PTK/ZK). Eur.J. Cancer (1999) 35(Suppl. 4):283. Abstract 1137.
118. FABBRO D, BUCHDUNGER E, WOOD J et al.: Inhibitors of protein kinases: CGP4l251i a protein kinase inhibitor with potential as an anti-cancer agent. PharmacoL Ther. (1999) 82:293-301.
119. BEGEMANN M, KASHIMAWO SA, HEITJAN DF et al.: Treatment of human glioblastoma cells with the staurosporine derivative CGP41251 inhibits CDC2 and CDK2 kinase activity and increases radiation sensitivity. AntiCancer Res. (1998) 18(4A):2275-2282.
120. VANGIJNR.VANTELLINGENO, HAVERKATE E et al.: Pharmacokinetics and metabolism of the staurosporine analogue CGP41251 in mice. Invest. New Drugs ( 1999) 17:29-41.
121. THAVASUP, PROPPERD, MCDONALD A etaL The protein kinase C inhibitor CGP41251 suppresses cytokine release and extracellular signal regulated kinase 2 expression in cancer patients. Cancer Res. (1999) 59(16):3980-3984.
122. LUOJC,YAMAGUCHIS,SHINKAIA et al.: Significant expression of vascular endothelial growth factor/vascular permeability factor in mouse ascites tumours. Cancer Res. (1998) 58:2652-2660.
123. YANOS.SHINOHARAH.KUNIYASU H et al.: Formation of pleural effusion by human lung adenocacinoma directly correlates with expression of VEGF/VPF. Proc. Am. Assoc. Cancer Res. (1999) 40:2279.
124. ZEBROWSKIBK, LIU W, RAMIREZ K et al.: Markedly elevated levels of vascular endothelial growth factor in malignant ascites. Ann. Surg. OncoL (1999) 6:373-378.
125. THICKETT DR, ARMSTRONG L, MILLAR AB et al.: Vascular endothelial growth factor in inflammatory and malignant pleural effusions. Thorax (1999) 54:707-710.
126. VERHUEL HM, HOEKMAN K, JORNA AS et al.: Targeting vascular endothelial growth factor blockade: Ascites and pleural
127. effusion formation. Oncologist (2000) 5(Suppl. 1):45-50.
128. YANOS, HERBST RS.SHINOHARA H et al.:. Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation. Gin. Cancer Res. (2000) 6(3):957-965-
129. AIELLO LP, WONG JS: Role of vascular endothelial growth factor in diabetic vascular complications. Kidney Int. (2000) 21(Suppl.77):113-119.
130. AIELLO LP, PIERCE EA, FOLEY ED et al.: Suppression of retinal neovascularisation in vivo by inhibition of vascular endothelial growth factor using soluble VEGF- receptor chimeric protein. Prof. NatL Acad. Set. USA (1995) 92:10457-10461.
131. ROBINSON GS, PIERCE EA, ROOK SL et al.: Oligo deoxyribonucleotides inhibit retinal neovascularisation in a murine model of proliferative retinopathy. Proc. NatL Acad. Sei. USA (1996) 93:4851-4856.
132. MIOTLAJ,MACIEWICZR,KENDREW J et al.: Treatment with soluble vascular endothelial growth factor receptor reduces disease severity in murine collagen induced arthritis. Lab. Invest. (2000) 80(8):11951205.
133. SMYTHAP,ROOKSL,DETMARM et al.: Antisense oligonucleotides inhibit vascular endothelial growth factor/vascular permeability factor expression in normal human epidermal keratinocytes. J. Invest. DennatoL (1997) 108(4):523-526.
134. KAMAT BR, BROWN LF, SENGER DR et al.: Expression of vascular permeability factor/vascular endothelial growth factor by human granulosa and theca lutein cell. Role in corpus luteum development. Am. J. PathoL (1995) 146(1):157-165.
135. BRASCHR,TURETSCHEKK:MRI characterisation of tumours and grading angiogenesis using macro molecular contrast media: status report. EUT. J. Radial. (2000)34(3):148-155.
136. • Describes utility of MMCM as a noninvasive technique for assessment of activity of anti-VEGF agents.
137. TOFTS PS, KERMODEAG: Measurement of the blood brain barrier permeability and space using dynamic MRI imaging. I. Fundamental concepts. Magn. Kfson. Meet. (1991) 17(2):357-367.
138. O' DONNELL A, TRIGO JM, BANERJI U et al.: A Phase I trial of the vascular endothelial growth factor inhibitor SU5416 incorporating dynamic contrast MRI
139. assessment of vascular permeability. Proc. ASCO (2000) Abstract 685.
140. MULLANI N, HERBST R, ABBRUZZESE J et al.: Anti angiogenic treatment with endostatin results in uncoupling of blood flow and glucose metabolism in human tumours. Gin. Positron imaging (2000) 3(4):151.
141. WALLHAUSTR, LACY J, WHANG J et al.: Human biodistribution and dosimetry of the PET perfusion copper-62-PTSM.J. NufL Med. (1998) 39(11):1958-1964.
142. BYRNEGJ.GHELLALA, BUNDRED NJ et al.: Serum soluble vascular cell adhesion molecule-1: role as surrogate marker for angiogenesis. J. NatL Cancer Inst. (2000) 92(16):1329-1336.
143. • Evaluates role of VCAM-1 as a surrogate marker for angiogenesis.
144. TEICHER BA, SOTOMAYOR EA, HUANG ZD: Anti-angiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease. Cancer Res. (1992) 52:6702-6704.
145. • Demonstrated synergistic activity of antiangiogenic agents with cytotoxic chemotherapy in in vivo models.
146. TEICHER BA, HOLDEN SA, ÄRA G et al.: Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other anti-angiogenicagents. Int.]. Czn
147. SCHLINGEMANN RO, VAN HINSBERGH VWM: Role of VPF/VEGF in eye disease. Br. J. OphthalmoL (1997) 81:501-512.
148. SUN L, TRAN N, TANG F et al.: Synthesis and biological evaluations of 3substituted Indolin-2-ones: A novel class of tyrosine kinase inhibitors that exhibit selectivity towards particular receptor tyrosine kinases.J. Med. Chem. (1998) 41:2588-2603.
149. SUN L, TRAN N.LIANG C et al.: Identification of substituted 3-1(4,5,6,7tetrahydro-lH-indoI-2-yl)methylene]-l,3dihydroindol-2-ones as growth factor receptor inhibitors for VEGF-R2(Flk-l/ KDR), FGF-R1, and PDGF-R tyrosine kinases.J. Med. Chem. (2000) 43:26552663.
150. HENNEQUINLF, THOMAS AP, JOHNSTONE C et al.: Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors./ Med. Chem. (1999) 42:53695389.
151. BOLD G, ALTMANN KH, FREI J et al.: New anilinophthalazincs as potent and
152. orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumour-driven angiogenesis. J. Mfd. Chem. (2000) 43:2310-2323.